Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMagyn050: Atezolizumab in Advanced Ovarian Cancer
NCT03038100Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2017
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of atezolizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Roche. Started Mar 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03038100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038100.